Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, however, is to examine the stocks held by highly successful companies. Recursion looks like a big dud so ...

Its use of artificial intelligence made the stock a hot buy earlier this year. However, Recursion isn't generating much revenue, and its cash burn is concerning. Earlier this year, hype around the ...

Recursion Pharmaceuticals (RXRX) closed the last trading session at $8.59, gaining 20% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Recursion announces that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share. Recursion expects to receive total gross proceeds of approximately $200 million. See ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...